The MEK effect on cancer — a slow and steady approach to drug resistance
PharmaVoice
JULY 8, 2025
You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it.
Let's personalize your content